| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 146, 1170-1177, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
MF Melhem, JC Law, L el-Ashmawy, JT Johnson, RJ Landreneau, S Srivastava and TL Whiteside
Department of Pathology, Veterans Administration Medical Center, Pittsburgh, PA 15240, USA.
Thirty-two primary carcinomas of the lung and 17 carcinomas of the head and neck (HN) were systematically analyzed for p53 mutations in the highly conserved regions of the gene (exons 5-8). Frozen sections of the same tumors were stained immunohistochemically to assess the sensitivity and specificity of p53 expression as determined by the presence or absence of the protein. On the basis of histology, the lung tumors studied were divided into adenocarcinomas (AC; n = 15), squamous- cell carcinomas (SCC; n = 12), and large-cell carcinomas (LCC; n = 5). All the HN cancers were SCC. Mutations in the p53 gene were detected by direct sequencing of amplified polymerase chain reaction products in six AC of the lungs (40%), three SCC of the lungs (25%), and one LCC (20%), with an overall mutation frequency of 31%. Nine AC (60%) of the lungs, five SCC (42%), and four LCC (80%) were p53-positive by immunohistochemistry. Among HN cancers, p53 mutations were detected in seven tumors (41%). Nine HN tumors (53%) were positive for p53. Negative staining, despite the presence of p53 mutations, was confined to nonsense mutations with truncated p53 and to single-base mutations not causing any change in the amino acid. Although immunohistochemical staining for mutated p53 is sensitive and simple to perform as a screening method, it is not as specific for evaluation of p53 mutations in lung and HN cancers.
This article has been cited by other articles:
 |
|
 |
|
  K.-W. Chang, S. Sarraj, S.-C. Lin, P.-I Tsai, and D. Solt p53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis Carcinogenesis, July 1, 2000; 21(7): 1441 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dong, Y. Nio, K. Tamura, M.-M. Song, K.-J. Guo, R.-X. Guo, and Y.-T. Dong Ki-ras Point Mutation and p53 Expression in Human Pancreatic Cancer: A Comparative Study among Chinese, Japanese, and Western Patients Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 279 - 284. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Temam, A. Flahault, S. Perie, G. Monceaux, F. Coulet, P. Callard, J.-F. Bernaudin, J. L. St Guily, and P. Fouret p53 Gene Status as a Predictor of Tumor Response to Induction Chemotherapy of Patients With Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck J. Clin. Oncol., January 14, 2000; 18(2): 385 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lassaletta, J. A. Brandariz, A. Benito, J. de la Cruz, C. Gomez, C. Ballestin, R. Hitt, R. Colomer, and J. J. Alvarez-Vicent p53 Expression in Locally Advanced Pharyngeal Squamous Cell Carcinoma Arch Otolaryngol Head Neck Surg, December 1, 1999; 125(12): 1356 - 1359. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Tammemagi, J. R. McLaughlin, and S. B. Bull Meta-Analyses of p53 Tumor Suppressor Gene Alterations and Clinicopathological Features in Resected Lung Cancers Cancer Epidemiol. Biomarkers Prev., July 1, 1999; 8(7): 625 - 634. [Abstract] [Full Text]
|
|
|
|
|
|
A. Yngveson, C. Williams, A. Hjerpe, J. Lundeberg, P. Söderkvist, and G. Pershagen p53 Mutations in Lung Cancer Associated with Residential Radon Exposure Cancer Epidemiol. Biomarkers Prev., May 1, 1999; 8(5): 433 - 438. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
